Biofront Therapeutics has identified fMet-Leu-Phe receptor (fMLP; FPR1) antagonists reported to be useful for the treatment of glioblastoma, traumatic brain injury and stroke.
Earth Chemical has patented lipoprotein lipase (LPL) activators reported to be useful for the treatment of hypertriglyceridemia. An exemplified compound rescued LPL from N-terminal GST-tagged angiopoietin-like 4 (ANGPTL4)-induced inactivation (EC50 = 1.01 mcM) in fluorescence-based assays.
Viking Therapeutics has divulged dual agonists of GLP-1 and glucose-dependent insulinotropic receptor (GDIR) reported to be useful for the treatment of nonalcoholic fatty liver disease (NAFLD).
Baylor College of Medicine has disclosed bromodomain testis-specific protein (BD2 domain) (BRDT-BD2) inhibitors reported to be useful for the treatment of male contraception and male infertility.
Chemokines are small signaling cytokines that are involved in many physiological processes such as host immune responses, wound healing and bone remodeling, with two of these chemokines, C-X-C motif chemokine 9 (CXCL9) and CXCL10, being involved in different osteoimmuno-modulating pathways.
Jemincare and its wholly owned subsidiary Shanghai Jemincare Pharmaceutical have signed an exclusive worldwide license agreement with Roche and Genentech for the development and commercialization of the androgen receptor degrader JMKX-002992.
Staphylococcus aureus is the most common bacterium recovered in orthopedic infections. Exebacase and CF-296 (ContraFect) are known to be anti-staphylococcal lysins with activity against S. aureus.